This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation CAR & T Cell Therapies

REGISTER BY FEBRUARY 10 FOR EARLY EVENT PLATFORM ACCESS

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
February 27 - March 2, 2023 | Part of BPI West
San Diego Convention CenterSan Diego, CA

Nathalie Belmonte
Sr VP Research & Translation at Quell Therapeutics

Profile

Nathalie is SVP Research & Translation at Quell Tx, developing CAR-Treg therapy. Before joining Quell Tx, Nathalie served as COO at Promethera Biosciences developing MSC-based therapy. Prior to that, she served as VP R&D at TxCell developing Treg cell-based therapy. She holds a PhD in Cell and Molecular Biology followed by a post-doctoral position at the Telethon Institute for Gene Therapy (TIGET) in Milan.

Agenda Sessions

  • Restoring the Immune Balance with Regulatory T cell Therapies in Inflammatory and Auto-immune Diseases

    11:00am